Lantheus Holdings Inc. (LNTH) Stock Price Down 1.1%
Lantheus Holdings Inc. (NASDAQ:LNTH) shares fell 1.1% on Friday . The stock traded as low as $9.35 and last traded at $9.40, with a volume of 286,896 shares traded. The stock had previously closed at $9.50.
Several brokerages recently weighed in on LNTH. Zacks Investment Research lowered Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. Jefferies Group reiterated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price objective on Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $6.60.
The company has a 50 day moving average of $6.18 and a 200-day moving average of $3.38. The stock has a market capitalization of $285.64 million and a PE ratio of 10.61.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.18. The company earned $78 million during the quarter, compared to the consensus estimate of $72.66 million. Equities analysts anticipate that Lantheus Holdings Inc. will post $0.54 earnings per share for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.